AstraZeneca, BMS Expand Development Of Diabetes Drug Dapagliflozin To Include Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - AstraZeneca K.K., a fully owned Japanese subsidiary of AstraZeneca, has announced plans to market type 2 diabetes treatment dapagliflozin jointly with Bristol-Meyers Squibb in Japan, a company spokesman said